Krystal Biotech, Inc. (KRYS)
USD 160.21
(-6.48%)
USD 160.21
(-6.48%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 160.42 Million USD | 16.33% |
| 2022 | 120.19 Million USD | 76.05% |
| 2021 | 68.27 Million USD | 106.9% |
| 2020 | 32.99 Million USD | 49.45% |
| 2019 | 22.08 Million USD | 85.31% |
| 2018 | 11.91 Million USD | 149.71% |
| 2017 | 4.77 Million USD | 317.5% |
| 2016 | 1.14 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 61.4 Million USD | 32.75% |
| 2024 Q1 | 41.22 Million USD | 11.37% |
| 2023 Q3 | 34.62 Million USD | 0.23% |
| 2023 Q4 | 37.01 Million USD | 6.9% |
| 2023 FY | 139.82 Million USD | 16.33% |
| 2023 Q1 | 38.04 Million USD | 4.75% |
| 2023 Q2 | 34.54 Million USD | -9.2% |
| 2022 Q4 | 36.32 Million USD | 4.46% |
| 2022 Q3 | 34.77 Million USD | 10.56% |
| 2022 Q2 | 31.45 Million USD | 9.38% |
| 2022 Q1 | 28.75 Million USD | 14.0% |
| 2022 FY | 120.19 Million USD | 76.05% |
| 2021 Q3 | 21.87 Million USD | 39.76% |
| 2021 FY | 68.27 Million USD | 106.9% |
| 2021 Q4 | 25.22 Million USD | 15.3% |
| 2021 Q1 | 16.39 Million USD | 14.21% |
| 2021 Q2 | 15.65 Million USD | -4.52% |
| 2020 Q4 | 14.35 Million USD | 37.74% |
| 2020 FY | 32.99 Million USD | 49.45% |
| 2020 Q3 | 10.42 Million USD | 7.64% |
| 2020 Q2 | 9.68 Million USD | 39.2% |
| 2020 Q1 | 6.95 Million USD | 16.95% |
| 2019 FY | 22.08 Million USD | 85.31% |
| 2019 Q4 | 5.94 Million USD | -3.38% |
| 2019 Q3 | 6.15 Million USD | 15.2% |
| 2019 Q2 | 5.34 Million USD | -9.3% |
| 2019 Q1 | 5.89 Million USD | 25.48% |
| 2018 Q1 | 2.44 Million USD | 7.55% |
| 2018 FY | 11.91 Million USD | 149.71% |
| 2018 Q3 | 4.21 Million USD | 41.96% |
| 2018 Q4 | 4.69 Million USD | 11.26% |
| 2018 Q2 | 2.97 Million USD | 21.36% |
| 2017 Q2 | 2.09 Million USD | 192.73% |
| 2017 Q1 | 715 Thousand USD | 53.76% |
| 2017 Q3 | 1.49 Million USD | -28.43% |
| 2017 Q4 | 2.27 Million USD | 52.0% |
| 2017 FY | 4.77 Million USD | 317.5% |
| 2016 FY | 1.14 Million USD | 0.0% |
| 2016 Q4 | 465 Thousand USD | -25.0% |
| 2016 Q2 | 322 Thousand USD | 0.0% |
| 2016 Q3 | 620 Thousand USD | 92.55% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 41.712% |
| Alkermes plc | 996.24 Million USD | 83.897% |
| Agenus Inc. | 78.18 Million USD | -105.193% |
| Aptorum Group Limited | 10.56 Thousand USD | -1518222.923% |
| Ardelyx, Inc. | 169.93 Million USD | 5.597% |
| Dyadic International, Inc. | 9.15 Million USD | -1652.773% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -620.919% |
| Lantern Pharma Inc. | 17.87 Million USD | -797.359% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -2283.056% |
| Novavax, Inc. | 779.12 Million USD | 79.409% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -97.905% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -95.175% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -726.15% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -441.87% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -201.97% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 57.838% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -560.01% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -323.634% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -421.355% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -89.369% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -818.978% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 4.756% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -390.374% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -0.4% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 91.088% |
| AlloVir, Inc. | 180.93 Million USD | 11.334% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 64.009% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -440.482% |
| Bicycle Therapeutics plc | 216.92 Million USD | 26.044% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 6.676% |
| ChromaDex Corporation | 56.37 Million USD | -184.549% |
| Chimerix, Inc. | 93.38 Million USD | -71.783% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1053.344% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -6.57% |
| CRISPR Therapeutics AG | 463.49 Million USD | 65.388% |
| Precision BioSciences, Inc. | 92.46 Million USD | -73.503% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 36.851% |
| Fortress Biotech, Inc. | 200.19 Million USD | 19.865% |
| Fortress Biotech, Inc. | 200.19 Million USD | 19.865% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -389.91% |
| ImmuCell Corporation | 9.61 Million USD | -1568.087% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -1.655% |
| Immix Biopharma, Inc. | 16.14 Million USD | -893.897% |
| Incyte Corporation | 1.19 Billion USD | 86.524% |
| Innoviva, Inc. | 132.15 Million USD | -21.393% |
| IO Biotech, Inc. | 91.44 Million USD | -75.438% |
| Jaguar Health, Inc. | 42.01 Million USD | -281.83% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 5.229% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -90.252% |
| ContextLogic Inc. | 387 Million USD | 58.546% |
| MiMedx Group, Inc. | 229.72 Million USD | 30.167% |
| MEI Pharma, Inc. | 34.78 Million USD | -361.193% |
| NextCure, Inc. | 67.63 Million USD | -137.187% |
| Onconetix, Inc. | 34.9 Million USD | -359.576% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1158.638% |
| Opthea Limited | 191.96 Million USD | 16.431% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -5730.312% |
| Vaxcyte, Inc. | 468.04 Million USD | 65.724% |
| PDS Biotechnology Corporation | 43.04 Million USD | -272.692% |
| Precigen, Inc. | 84.18 Million USD | -90.573% |
| Pharming Group N.V. | 225.49 Million USD | 28.855% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 4.41% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -121.076% |
| PureTech Health plc | 144.59 Million USD | -10.947% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -23.155% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 34.562% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -560.01% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 29.847% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -419.868% |
| Acelyrin, Inc. | 422.06 Million USD | 61.99% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1244091.097% |
| Summit Therapeutics Inc. | 87.68 Million USD | -82.955% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -332.835% |
| Senti Biosciences, Inc. | 94.7 Million USD | -69.395% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -29.844% |
| Elevation Oncology, Inc. | 45.44 Million USD | -253.011% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -444.389% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -3969.611% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -21.374% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -370.665% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -1798.308% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 11.514% |
| Seer, Inc. | 110.49 Million USD | -45.195% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -127.252% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -71.619% |
| ESSA Pharma Inc. | 32.13 Million USD | -399.239% |
| GlycoMimetics, Inc. | 39.28 Million USD | -308.361% |
| GT Biopharma, Inc. | 13.57 Million USD | -1081.688% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 27.023% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 20.232% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 38.161% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -182.644% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -196.646% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -1514.326% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 60.248% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -747.514% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -216.466% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 38.217% |
| Aptose Biosciences Inc. | 52.35 Million USD | -206.414% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1013.267% |
| Soligenix, Inc. | 7.79 Million USD | -1957.997% |
| Century Therapeutics, Inc. | 56.07 Million USD | -186.112% |
| Kura Oncology, Inc. | 165.8 Million USD | 3.244% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -40.101% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -1828.429% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -6364.518% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -48.959% |
| Autolus Therapeutics plc | 196.72 Million USD | 18.452% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -89.501% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -37.76% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -727.663% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 50.141% |
| GRI Bio, Inc. | 11.33 Million USD | -1315.94% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -2173.707% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -22.282% |
| IGM Biosciences, Inc. | 265.59 Million USD | 39.597% |
| INmune Bio, Inc. | 29.89 Million USD | -436.614% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 7.029% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -297.938% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -903.958% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -919.124% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -158.343% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -49.203% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 41.81% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 46.782% |
| Verastem, Inc. | 92.08 Million USD | -74.217% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -794.286% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 13.622% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -32.139% |
| Histogen Inc. | 14.27 Million USD | -1024.061% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -899.655% |
| Surrozen, Inc. | 18.55 Million USD | -764.83% |
| Organovo Holdings, Inc. | 14.91 Million USD | -975.602% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3051.642% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -168.841% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -525.516% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -241.288% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2001.786% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 9.942% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -231.131% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 34.521% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -943.993% |
| Apollomics, Inc. | 54.14 Million USD | -196.317% |
| Amarin Corporation plc | 272.35 Million USD | 41.097% |
| Mesoblast Limited | 5.9 Million USD | -2618.163% |
| Turnstone Biologics Corp. | 78.33 Million USD | -104.787% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 34.284% |
| Synaptogenix, Inc. | 8.31 Million USD | -1829.623% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -999.863% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 36.605% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -381.325% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -1716.575% |
| Exelixis, Inc. | 1.58 Billion USD | 89.89% |
| Better Therapeutics, Inc. | 38.26 Million USD | -319.283% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 30.866% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 81.241% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1258.729% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -1894.875% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -434.878% |
| Gritstone bio, Inc. | 148.37 Million USD | -8.123% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -132.971% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -880.586% |
| Avid Bioservices, Inc. | 25.99 Million USD | -517.118% |
| Insmed Incorporated | 949.26 Million USD | 83.1% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -922.487% |
| MediWound Ltd. | 18.86 Million USD | -750.254% |
| OmniAb, Inc. | 83.89 Million USD | -91.222% |
| Alector, Inc. | 248.8 Million USD | 35.521% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 31.532% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -207.03% |
| Zai Lab Limited | 547.47 Million USD | 70.697% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 59.758% |
| Aura Biosciences, Inc. | 84.99 Million USD | -88.756% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 35.086% |
| Immunic, Inc. | 99.22 Million USD | -61.682% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -0.889% |
| Veracyte, Inc. | 357.93 Million USD | 55.18% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 98.221% |
| FibroGen, Inc. | 398.11 Million USD | 59.703% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1028.966% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -2229.083% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -2151.362% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 95.072% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -520.052% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 49.319% |
| TG Therapeutics, Inc. | 198.47 Million USD | 19.171% |
| Galecto, Inc. | 35.62 Million USD | -350.293% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -294.274% |
| Fortrea Holdings Inc. | 457.3 Million USD | 64.919% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -195.564% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -455.53% |
| XBiotech Inc. | 37.51 Million USD | -327.689% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -132.971% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -676.919% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -12.928% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -61.924% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -44.899% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 83.258% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -456.166% |
| Vaxxinity, Inc. | 56.05 Million USD | -186.214% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 62.747% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -619.131% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -44.701% |
| NexImmune, Inc. | 28.16 Million USD | -469.543% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -2800.515% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -796.61% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 94.302% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -530.135% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1269.421% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -26.258% |
| Ainos, Inc. | 12.95 Million USD | -1138.556% |
| Pluri Inc. | 22.48 Million USD | -613.639% |
| Prothena Corporation plc | 282.4 Million USD | 43.193% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 19.796% |
| Celularity Inc. | 215.05 Million USD | 25.403% |
| Rallybio Corporation | 78.93 Million USD | -103.246% |
| Cue Biopharma, Inc. | 19.54 Million USD | -720.929% |
| MeiraGTx Holdings plc | 151.07 Million USD | -6.188% |
| Omeros Corporation | 94.75 Million USD | -69.313% |
| Humacyte, Inc. | 23.49 Million USD | -582.751% |
| Immunocore Holdings plc | 308.04 Million USD | 47.92% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -4632.33% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -84.684% |
| Blueprint Medicines Corporation | 722.86 Million USD | 77.807% |
| CalciMedica, Inc. | 21.81 Million USD | -635.326% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -114.875% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 0.071% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 6.345% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 45.607% |
| Pulmatrix, Inc. | 22.03 Million USD | -627.952% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -363.994% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -80.526% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 70.914% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -121.122% |
| Cytokinetics, Incorporated | 173.61 Million USD | 7.595% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -366.097% |
| Nutriband Inc. | 5.73 Million USD | -2697.787% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -267.84% |
| Vor Biopharma Inc. | 126.03 Million USD | -27.286% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 86.51% |
| Evogene Ltd. | 27.79 Million USD | -477.28% |
| ProKidney Corp. | 151.52 Million USD | -5.876% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -116.28% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -1985.556% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 73.882% |
| CorMedix Inc. | 48.95 Million USD | -227.682% |
| BioLineRx Ltd. | 50.8 Million USD | -215.787% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -6.454% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -321.375% |
| Atai Life Sciences N.V. | 125.78 Million USD | -27.54% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -96.506% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -97.062% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 36.478% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -390.0% |
| MediciNova, Inc. | 10.9 Million USD | -1371.762% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -24.535% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2109.869% |
| GeoVax Labs, Inc. | 6.02 Million USD | -2563.922% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 66.323% |
| Biomea Fusion, Inc. | 126.13 Million USD | -27.186% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 87.771% |
| Mereo BioPharma Group plc | 35.84 Million USD | -347.592% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 16.046% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 30.236% |
| Absci Corporation | 73.66 Million USD | -117.775% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -481.633% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -20.088% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 33.753% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 38.78% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 22.87% |
| Allakos Inc. | 196.05 Million USD | 18.173% |
| Imunon, Inc. | 20.31 Million USD | -689.87% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -41.383% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 56.478% |
| BioAtla, Inc. | 129.68 Million USD | -23.702% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1258.729% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -912.599% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -88.919% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -284.18% |
| XOMA Corporation | 46.46 Million USD | -245.277% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -44.306% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -12.609% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1136.043% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -54.768% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 7.198% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 37.03% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -328.855% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -1850.512% |
| Akari Therapeutics, Plc | 16.8 Million USD | -854.576% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -6954.886% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 46.403% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2284.194% |
| UroGen Pharma Ltd. | 138.88 Million USD | -15.507% |
| Sutro Biopharma, Inc. | 243 Million USD | 33.984% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -2105.283% |
| Orgenesis Inc. | 45.75 Million USD | -250.604% |
| Entera Bio Ltd. | 8.86 Million USD | -1710.677% |
| GH Research PLC | 41.22 Million USD | -289.176% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -524.031% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -93.161% |
| Xencor, Inc. | 306.97 Million USD | 47.74% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -3151.699% |
| Replimune Group, Inc. | 234.77 Million USD | 31.668% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -682.952% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 16.356% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2284.194% |
| Portage Biotech Inc. | 18.19 Million USD | -781.51% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2109.869% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -52.843% |
| OncoCyte Corporation | 25.63 Million USD | -525.76% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -2531.83% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1300.237% |
| Purple Biotech Ltd. | -22.46 Million USD | 814.052% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -873.459% |
| scPharmaceuticals Inc. | 65.17 Million USD | -146.135% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -1797.918% |
| HilleVax, Inc. | 133.34 Million USD | -20.309% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -1459.806% |
| Tharimmune, Inc. | 9.45 Million USD | -1596.692% |
| Genprex, Inc. | 31.06 Million USD | -416.494% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 14.451% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -411.285% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -20870.719% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -2845.261% |
| OKYO Pharma Limited | 8243.57 USD | -1945974.334% |
| Savara Inc. | 15.74 Million USD | -918.901% |
| Curis, Inc. | 58.35 Million USD | -174.914% |
| Daré Bioscience, Inc. | 33.6 Million USD | -377.325% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -3050.248% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2050.194% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -493.687% |
| BeiGene, Ltd. | 3.28 Billion USD | 95.119% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -704.572% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 67.835% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -4.409% |
| Erasca, Inc. | 141.52 Million USD | -13.355% |
| bluebird bio, Inc. | 240.23 Million USD | 33.22% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -3443.78% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 90.813% |
| DBV Technologies S.A. | 92.16 Million USD | -74.073% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -3443.78% |
| Moderna, Inc. | 6.39 Billion USD | 97.491% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -276.507% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1016.706% |
| Molecular Templates, Inc. | 63.09 Million USD | -154.277% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -140.515% |
| Travere Therapeutics, Inc. | 472 Million USD | 66.012% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -11.943% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -158.41% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -269.526% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 22.92% |
| MacroGenics, Inc. | 217.21 Million USD | 26.144% |
| RenovoRx, Inc. | 11.39 Million USD | -1307.74% |
| Adicet Bio, Inc. | 152.03 Million USD | -5.517% |
| Prime Medicine, Inc. | 186.63 Million USD | 14.045% |
| Aditxt, Inc. | 25.95 Million USD | -518.194% |
| Adagene Inc. | 41.83 Million USD | -283.507% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2094.581% |
| Quantum-Si incorporated | 111.65 Million USD | -43.675% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 6.648% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1000.484% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -347.842% |
| SciSparc Ltd. | 9.01 Million USD | -1680.335% |
| Vericel Corporation | 142.04 Million USD | -12.944% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -1753.208% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -594.828% |
| Generation Bio Co. | 144.46 Million USD | -11.047% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -93.215% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -85.549% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 45.751% |
| Invivyd, Inc. | 205.75 Million USD | 22.031% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -122.323% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -1610.571% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -113.179% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -1459.502% |
| 2seventy bio, Inc. | 289.88 Million USD | 44.659% |
| ADMA Biologics, Inc. | 66.58 Million USD | -140.931% |
| Clene Inc. | 41.07 Million USD | -290.587% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1152.556% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -192.77% |
| GeoVax Labs, Inc. | 6.02 Million USD | -2563.922% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 54.431% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -336.747% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -375.646% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -54.699% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -392.27% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 5.786% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 79.104% |
| Evaxion Biotech A/S | 22.27 Million USD | -620.368% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -18.357% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 31.699% |
| Trevena, Inc. | 38.41 Million USD | -317.635% |
| Surrozen, Inc. | 18.55 Million USD | -764.83% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -100.67% |
| Cingulate Inc. | 22.75 Million USD | -604.885% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 2241.297% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -259.16% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -1848.35% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -56.425% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 78.726% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -158.443% |
| Clearmind Medicine Inc. | 8.74 Million USD | -1735.254% |
| Kronos Bio, Inc. | 128.11 Million USD | -25.217% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -90.82% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -5369.718% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -59.11% |
| Statera Biopharma, Inc. | 28.82 Million USD | -456.465% |
| ImmunityBio, Inc. | 362.87 Million USD | 55.79% |
| Korro Bio, Inc. | 84.53 Million USD | -89.777% |
| Kineta, Inc. | 21.15 Million USD | -658.3% |
| BioVie Inc. | 31.95 Million USD | -402.113% |
| Codexis, Inc. | 66.51 Million USD | -141.177% |
| Celularity Inc. | 215.05 Million USD | 25.403% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 29.21% |
| Celcuity Inc. | 66.23 Million USD | -142.224% |
| Virax Biolabs Group Limited | 6.54 Million USD | -2350.351% |
| Cibus, Inc. | 320.3 Million USD | 49.915% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -273.084% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -374.016% |
| IN8bio, Inc. | 30.33 Million USD | -428.813% |
| Kodiak Sciences Inc. | 277.32 Million USD | 42.152% |
| Annexon, Inc. | 143.72 Million USD | -11.622% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -25.735% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -600.275% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -24966.563% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 79.422% |
| Eyenovia, Inc. | 25.4 Million USD | -531.438% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -14.333% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -2784.322% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -102.73% |
| Arcellx, Inc. | 200.19 Million USD | 19.867% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -249.512% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 25.87% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -1511.188% |
| Moolec Science SA | 52.75 Million USD | -204.122% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -162.4% |
| Geron Corporation | 70.44 Million USD | -127.745% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -244.706% |
| Royalty Pharma plc | 862.4 Million USD | 81.398% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -70.535% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -1619.857% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -608.954% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 22.802% |
| Humacyte, Inc. | 23.49 Million USD | -582.751% |
| Structure Therapeutics Inc. | 102.77 Million USD | -56.094% |
| 89bio, Inc. | 151.2 Million USD | -6.099% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -100.202% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1003.343% |
| Genelux Corporation | 24.33 Million USD | -559.24% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -372.912% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 7.198% |
| Notable Labs, Ltd. | 14.77 Million USD | -986.161% |
| Liquidia Corporation | 87.98 Million USD | -82.335% |
| Mustang Bio, Inc. | 48.5 Million USD | -230.768% |
| Immunovant, Inc. | 282.7 Million USD | 43.254% |
| Quantum-Si incorporated | 111.65 Million USD | -43.675% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -611.613% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -654.342% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -57.262% |
| Acasti Pharma Inc. | 11.3 Million USD | -1319.573% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -599.905% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -903.958% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -244.691% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -14039.682% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -909.858% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -450.214% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -287.652% |
| PepGen Inc. | 84.76 Million USD | -89.257% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -441.413% |
| United Therapeutics Corporation | 885.1 Million USD | 81.875% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -600.642% |
| Solid Biosciences Inc. | 104.31 Million USD | -53.79% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -390.217% |
| Immuneering Corporation | 58.41 Million USD | -174.641% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3051.642% |
| Silo Pharma, Inc. | 3.92 Million USD | -3990.563% |
| Belite Bio, Inc | 31.66 Million USD | -406.587% |
| XOMA Corporation | 46.46 Million USD | -245.277% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -137.492% |
| Bionomics Limited | 17.89 Billion USD | 99.103% |
| Apogee Therapeutics, Inc. | 93 Million USD | -72.496% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 549.624% |
| uniQure N.V. | 285.08 Million USD | 43.727% |
| Cassava Sciences, Inc. | 105.95 Million USD | -51.407% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2094.581% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 17.394% |
| Forte Biosciences, Inc. | 32.47 Million USD | -393.968% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -1830.807% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -445.759% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -2784.322% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1028.966% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -1704.77% |
| Altimmune, Inc. | 30.55 Million USD | -425.023% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 62.487% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 549.624% |
| Compugen Ltd. | 43.97 Million USD | -264.845% |
| Peak Bio, Inc. | 1249.13 USD | -12842918.741% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -116.441% |
| Benitec Biopharma Inc. | 22.38 Million USD | -616.763% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 34.032% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -462.05% |
| Zura Bio Limited | 62.63 Million USD | -156.116% |
| PolyPid Ltd. | 21.04 Million USD | -662.3% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -885.66% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -462.05% |
| Instil Bio, Inc. | 85.78 Million USD | -87.009% |
| argenx SE | 1.53 Billion USD | 89.539% |
| Immunome, Inc. | 122.82 Million USD | -30.619% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -230.96% |
| Verona Pharma plc | 67.15 Million USD | -138.902% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -519.764% |
| Shattuck Labs, Inc. | 93.61 Million USD | -71.37% |
| CervoMed Inc. | 14.95 Million USD | -972.526% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -126.901% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -1777.645% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -214.561% |
| Moolec Science SA | 52.75 Million USD | -204.122% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -875.327% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -21.026% |
| AnaptysBio, Inc. | 181.56 Million USD | 11.644% |
| Design Therapeutics, Inc. | 78.19 Million USD | -105.175% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -84.311% |
| NeurAxis, Inc. | 8.82 Million USD | -1718.642% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1174.74% |
| Lumos Pharma, Inc. | 38.66 Million USD | -314.913% |
| Achilles Therapeutics plc | 75.25 Million USD | -113.177% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -519.764% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1090.325% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -505.325% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -5369.718% |
| Nutriband Inc. | 5.73 Million USD | -2697.787% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -44.815% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -188.261% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -215.309% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -142.706% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -196.41% |
| Palisade Bio, Inc. | 13.32 Million USD | -1104.399% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -253.291% |
| Beam Therapeutics Inc. | 554.19 Million USD | 71.052% |
| Neurogene Inc. | 55.58 Million USD | -188.624% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 35.439% |
| AEON Biopharma, Inc. | 48.42 Million USD | -231.26% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -65.884% |
| Sesen Bio, Inc. | 78.38 Million USD | -104.675% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -92.06% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1174.548% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 64.428% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -82.53% |
| Athira Pharma, Inc. | 125.46 Million USD | -27.864% |
| Vaccinex, Inc. | 23.45 Million USD | -583.974% |
| HCW Biologics Inc. | 21.02 Million USD | -662.934% |
| XOMA Corporation | 46.46 Million USD | -245.277% |
| Nektar Therapeutics | 190.9 Million USD | 15.965% |
| Arvinas, Inc. | 480 Million USD | 66.578% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -6954.886% |
| Merus N.V. | 200.49 Million USD | 19.985% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -55.218% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -363.391% |
| Rezolute, Inc. | 70.38 Million USD | -127.92% |
| Clene Inc. | 41.07 Million USD | -290.587% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -879.493% |
| BeyondSpring Inc. | 24.86 Million USD | -545.188% |
| Synlogic, Inc. | 58.53 Million USD | -174.083% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -796.635% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -3471.371% |
| Peak Bio, Inc. | 1249.13 USD | -12842918.741% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -165.404% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 40.721% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 53.906% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -7338.377% |
| MannKind Corporation | 125.59 Million USD | -27.731% |
| Ikena Oncology, Inc. | 84.57 Million USD | -89.68% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -1562.963% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -79.045% |
| Gossamer Bio, Inc. | 183.75 Million USD | 12.698% |
| CohBar, Inc. | 12.38 Million USD | -1194.98% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -216.272% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -481.633% |
| Legend Biotech Corporation | 583.14 Million USD | 72.49% |
| Mural Oncology plc | 192.07 Million USD | 16.476% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -138.918% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -893.641% |
| Disc Medicine, Inc. | 91.12 Million USD | -76.05% |
| Champions Oncology, Inc. | 28.11 Million USD | -470.708% |
| REGENXBIO Inc. | 321.15 Million USD | 50.047% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -2892.333% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -187.729% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -311.764% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -40.285% |
| Vaxart, Inc. | 90.72 Million USD | -76.825% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -1782.933% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -274.879% |
| Cellectis S.A. | 97.32 Million USD | -64.844% |
| Longeveron Inc. | 21.25 Million USD | -654.946% |
| Repare Therapeutics Inc. | 167.35 Million USD | 4.141% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 88.211% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -112.077% |
| Revolution Medicines, Inc. | 498.76 Million USD | 67.835% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -2311.696% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -264.986% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -115.077% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -130.381% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1350.506% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 96.64% |
| Denali Therapeutics Inc. | 527.23 Million USD | 69.572% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -1753.208% |
| Veru Inc. | 101.34 Million USD | -58.292% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -585.376% |
| Cingulate Inc. | 22.75 Million USD | -604.885% |
| Passage Bio, Inc. | 108.38 Million USD | -48.009% |
| Context Therapeutics Inc. | 25.07 Million USD | -539.845% |
| Exicure, Inc. | 14.07 Million USD | -1039.713% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 22.147% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -270.49% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -1648.076% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 36.461% |
| Nuvalent, Inc. | 149.49 Million USD | -7.314% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -1888.694% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -54.777% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -647.942% |
| OmniAb, Inc. | 83.89 Million USD | -91.222% |
| Anew Medical, Inc. | 1.3 Million USD | -12232.483% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -389.641% |
| Lipocine Inc. | 15.08 Million USD | -963.823% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -134.154% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -110.666% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -297.938% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -39.692% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -616.699% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 75.845% |
| Ocugen, Inc. | 71.56 Million USD | -124.162% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -70.91% |
| Q32 Bio Inc. | 92.68 Million USD | -73.097% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -657.656% |
| Alumis Inc. Common Stock | 158.17 Million USD | -1.424% |
| Equillium, Inc. | 50.6 Million USD | -217.01% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -157.068% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1053.683% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -750.385% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -241.688% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -47.904% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1194.517% |
| Dominari Holdings Inc. | 23.83 Million USD | -573.069% |
| Edesa Biotech, Inc. | 9.22 Million USD | -1639.458% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1247.325% |
| Bio-Techne Corporation | 563.03 Million USD | 71.507% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 60.757% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 40.308% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -21.28% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1013.219% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 1.998% |
| Nkarta, Inc. | 131.65 Million USD | -21.858% |
| BioCardia, Inc. | 12.12 Million USD | -1223.538% |
| Iterum Therapeutics plc | 47.46 Million USD | -237.967% |